These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma. Nio K, Yamashita T, Okada H, Kondo M, Hayashi T, Hara Y, Nomura Y, Zeng SS, Yoshida M, Hayashi T, Sunagozaka H, Oishi N, Honda M, Kaneko S. J Hepatol; 2015 Nov; 63(5):1164-72. PubMed ID: 26095183 [Abstract] [Full Text] [Related]
5. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. Terris B, Cavard C, Perret C. J Hepatol; 2010 Feb; 52(2):280-1. PubMed ID: 20006402 [Abstract] [Full Text] [Related]
6. Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma. Wang H, Kohashi K, Yoshizumi T, Okumura Y, Tanaka Y, Shimokawa M, Iwasaki T, Aishima S, Maehara Y, Oda Y. Hum Pathol; 2017 Jun; 64():69-75. PubMed ID: 28411180 [Abstract] [Full Text] [Related]
7. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, Tang ZY, Wang XW. Cancer Res; 2008 Mar 01; 68(5):1451-61. PubMed ID: 18316609 [Abstract] [Full Text] [Related]
8. High expression of MAGE-A9 contributes to stemness and malignancy of human hepatocellular carcinoma. Wei Y, Wang Y, Gong J, Rao L, Wu Z, Nie T, Shi D, Zhang L. Int J Oncol; 2018 Jan 01; 52(1):219-230. PubMed ID: 29138811 [Abstract] [Full Text] [Related]
9. Spalt-like transcription factor 4 immunopositivity is associated with epithelial cell adhesion molecule expression in combined hepatocellular carcinoma and cholangiocarcinoma. Tanaka Y, Aishima S, Kohashi K, Okumura Y, Wang H, Hida T, Kotoh K, Shirabe K, Maehara Y, Takayanagi R, Oda Y. Histopathology; 2016 Apr 01; 68(5):693-701. PubMed ID: 26267070 [Abstract] [Full Text] [Related]
10. α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression. Ikeda H, Sato Y, Yoneda N, Harada K, Sasaki M, Kitamura S, Sudo Y, Ooi A, Nakanuma Y. Hum Pathol; 2012 Nov 01; 43(11):1955-63. PubMed ID: 22516245 [Abstract] [Full Text] [Related]
11. Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. Yamashita T, Honda M, Nio K, Nakamoto Y, Yamashita T, Takamura H, Tani T, Zen Y, Kaneko S. Cancer Res; 2010 Jun 01; 70(11):4687-97. PubMed ID: 20484035 [Abstract] [Full Text] [Related]
13. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, Reid LM, Minato H, Honda M, Kaneko S, Tang ZY, Wang XW. Gastroenterology; 2009 Mar 01; 136(3):1012-24. PubMed ID: 19150350 [Abstract] [Full Text] [Related]
14. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Ushiku T, Shinozaki A, Shibahara J, Iwasaki Y, Tateishi Y, Funata N, Fukayama M. Am J Surg Pathol; 2010 Apr 01; 34(4):533-40. PubMed ID: 20182341 [Abstract] [Full Text] [Related]
15. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ, Shi RY, Hu B, Zhou J, Fan J. Hepatology; 2013 Apr 01; 57(4):1458-68. PubMed ID: 23175471 [Abstract] [Full Text] [Related]
16. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, Pantel K, Riethdorf S, Wege H. Int J Cancer; 2013 Nov 01; 133(9):2165-71. PubMed ID: 23616258 [Abstract] [Full Text] [Related]
17. Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Tan PS, Nakagawa S, Goossens N, Venkatesh A, Huang T, Ward SC, Sun X, Song WM, Koh A, Canasto-Chibuque C, Deshmukh M, Nair V, Mahajan M, Zhang B, Fiel MI, Kobayashi M, Kumada H, Hoshida Y. Liver Int; 2016 Jan 01; 36(1):108-18. PubMed ID: 26058462 [Abstract] [Full Text] [Related]
18. Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status. Shan YF, Huang YL, Xie YK, Tan YH, Chen BC, Zhou MT, Shi HQ, Yu ZP, Song QT, Zhang QY. Med Oncol; 2011 Dec 01; 28(4):1012-6. PubMed ID: 20571936 [Abstract] [Full Text] [Related]
19. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, Yamashita T, Mizukoshi E, Ikeda H, Zen Y, Takamura H, Wang XW, Kaneko S. Hepatology; 2013 Apr 01; 57(4):1484-97. PubMed ID: 23174907 [Abstract] [Full Text] [Related]
20. Hepatitis B virus X protein induces hepatic stem cell-like features in hepatocellular carcinoma by activating KDM5B. Wang X, Oishi N, Shimakami T, Yamashita T, Honda M, Murakami S, Kaneko S. World J Gastroenterol; 2017 May 14; 23(18):3252-3261. PubMed ID: 28566884 [Abstract] [Full Text] [Related] Page: [Next] [New Search]